Today: 27 April 2026
Browse Category

SWX:EMMN.SW 26 November 2025

Swiss Stock Market Today, 26 November 2025: SMI Edges Higher as Sentiment Surges and Insurers Face Tougher Rules

Swiss Stock Market Today, 26 November 2025: SMI Edges Higher as Sentiment Surges and Insurers Face Tougher Rules

The Swiss Market Index closed up 0.07% at 12,781.09 on Wednesday, its highest in about a week, extending a three-day advance. Turnover topped 2.4 million contracts. Investor sentiment jumped after a thaw in Swiss-US trade tensions. Zurich Insurance, Swiss Re, and Swiss Life drew attention after being added to the G20 Financial Stability Board’s insurer resolution list.
26 November 2025
········

Stock Market Today

  • Dollar Dips on Iran Peace Hopes, Oil Prices Rise
    April 27, 2026, 5:35 PM EDT. The U.S. dollar dipped from a 2.5-week high amid reports that Iran proposed reopening the Strait of Hormuz, a strategic oil passage, suggesting potential easing of US-Iran tensions. Axios reported the plan includes extending the ceasefire before nuclear talks, with the White House reviewing the proposal. Despite higher crude oil prices lifting inflation expectations-a factor that usually strengthens the dollar-uncertainty over US Federal Reserve interest rate moves and rate hike cutbacks in 2026 weighed on the currency. The dollar index fell 0.05%, while the euro saw modest gains supported by dollar weakness but constrained by weak German consumer and business confidence. The yen weakened slightly amid Japan's rising stock market and higher bond yields. Markets now price near zero chance of a Fed rate hike at this week's meeting.

Latest article

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

27 April 2026
Oruka Therapeutics reported its experimental psoriasis drug ORKA-001 achieved complete skin clearance in 63.5% of patients at 16 weeks. Shares jumped 10.5% to $76.39 before the company launched a $500 million public offering. No serious adverse events were reported in the trial. ORKA-001 is being developed as a long-acting injectable, with annual dosing possible.
Why Rambus Stock Fell Even as AI Memory Sales Jumped in Q1

Why Rambus Stock Fell Even as AI Memory Sales Jumped in Q1

27 April 2026
Rambus shares fell 10.8% to $141.31 Monday after reporting first-quarter revenue of $180.2 million and net income of $59.9 million. Product revenue rose 15% to $88 million, driven by AI data-center demand. The company forecast higher second-quarter product revenue but said results depend on customer deals. Rambus recently launched a new server memory module aimed at AI systems.
Go toTop